How much is the bleeding disorder testing market worth, and how is it expected to expand?
The bleeding disorder testing market size has grown strongly in recent years. It will grow from $14.99 billion in 2024 to $16.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing prevalence of bleeding disorders, increasing investment in research and development, a growing number of specialized clinics, increasing demand for early diagnosis, and a rising number of clinical trials.
The bleeding disorder testing market size is expected to see strong growth in the next few years. It will grow to $22.02 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the increasing prevalence of hemophilia rising awareness of bleeding disorder symptoms, increasing investment in diagnostic research, rising healthcare spending globally, and rising prevalence of rare bleeding disorders. Major trends in the forecast period include technological advancements, integration of artificial intelligence, personalized medicine, telemedicine services, and home-based testing kits.
Get Your Free Sample of The Global Bleeding Disorder Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18263&type=smp
Which industry factors have accelerated the bleeding disorder testing market’s expansion?
The increasing number of clinical trials is expected to propel the growth of the bleeding disorder testing market going forward. Clinical trials are research studies that assess the safety and efficacy of novel medical treatments, therapies, medicines, or technology in humans. The increase in clinical trials is due to advancements in medical research, growing investment in healthcare innovation, and rising demand for new treatments and therapies. Bleeding disorder testing is used in clinical trials to evaluate the efficacy and safety of new medicines and therapies for bleeding disorders, assess how well these treatments manage or correct clotting abnormalities, and monitor patient responses to ensure optimal dosing and effectiveness. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, around 477,228 clinical trials were registered at the end of 2023, an increase from 437,507 in 2022. Therefore, the increasing number of clinical trials is driving the growth of the bleeding disorder testing market.
What are the primary segments of the bleeding disorder testing market?
The bleeding disorder testing market covered in this report is segmented –
1) By Product Type: Reagents And Consumables, Instruments
2) By Indication: Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura, Other Indications
3) By Treatment Type: Factor Replacement Therapy, Drug Therapy
4) By End User: Hospitals And Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Reagents And Consumables: Coagulation Reagents, Plasma And Blood Collection Consumables, Hemostasis Reagents, Factor Deficiency Assay Kits, Activated Partial Thromboplastin Time (APTT) Reagents
2) By Instruments: Coagulation Analyzers, Platelet Function Analyzers, Hemostasis Testing Instruments, Point-Of-Care Testing Devices, Automated Blood Testing Systems
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report
Which firms are leading the bleeding disorder testing market?
Major companies operating in the bleeding disorder testing market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Siemens Healthcare GmbH, Baxter International Inc., CSL Limited, Octapharma AG, HORIBA Ltd., Haemonetics Corporation, Diagnostica Stago S.A.S., Sekisui Diagnostics LLC, Helena Laboratories Corporation, LFB Group, Sysmex Inostics GmbH, Medexus Pharmaceuticals Inc., Precision Biologics Inc., Corgenix Inc., Diapharma Group Inc., Hyphen BioMed, Hema Biologics LLC
Which market trends are set to define the future of the bleeding disorder testing market?
Major companies operating in the bleeding disorder testing market are focused on developing innovative products, such as gene therapy for Hemophilia B, to provide long-term solutions, cure genetic bleeding disorders, enhance treatment outcomes, and expand their market reach. Hemophilia B is a type of bleeding disorder. It is characterized by a deficiency of clotting factor IX, which is essential for proper blood coagulation. Gene therapy for Hemophilia B is an emerging treatment aimed at providing a long-term solution by addressing the underlying genetic defect responsible for the condition. For instance, in February 2023, CSL Limited, an Australia-based biotechnology company, and the European Commission approved conditional marketing authorization (CMA) for HEMGENIX, the first and only one-time gene therapy for treating severe and moderately severe hemophilia B. This one-time treatment aims to provide long-lasting efficacy, reducing or eliminating the need for regular factor replacement therapy. HEMGENIX is notable for its innovative approach to gene therapy, offering a transformative option for patients with hemophilia B and potentially changing the standard of care in the field.
Which geographic trends are shaping the bleeding disorder testing market, and which region has the highest market share?
North America was the largest region in the bleeding disorder testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorder testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Bleeding Disorder Testing Market Report 2025 Offer?
The bleeding disorder testing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Bleeding disorder testing refers to a range of diagnostic procedures used to evaluate the function and composition of blood to identify abnormalities related to bleeding disorders. These tests assess clotting ability, platelet function, and specific clotting factor deficiencies or dysfunctions.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18263
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
